Efficacy and safety of conversion of mycophenolate mofetil to enteric-coated mycophenolate sodium in Mexican renal transplant children

Reyes H, Hernández AM, Valverde S, Cataneo A, Mendoza A, Barrera I, Ortíz L, García‐Roca P, Lopéz‐Martínez B, Castañeda‐Hernández G, Medeiros M. Efficacy and safety of conversion of mycophenolate mofetil to enteric‐coated mycophenolate sodium in Mexican renal transplant children. Pediatr Transplantation 2010: 14:746–752. © 2010 John Wiley & Sons A/S. : The aim of the study was to evaluate the efficacy and safety of the conversion of MMF to EC‐MPS in pediatric renal transplant recipients. We included 12 patients with stable graft function who were receiving MMF treatment. In the first visit, a complete medical examination was performed, which included a GSRS, a nine‐point pharmacokinetic profile, samples for renal, liver and hematological tests and evaluation of IMPDH2 gene expression. The patients were transferred to an equimolar dose of EC‐MPS. Two wk later, a clinical evaluation and blood collection, as in the first visit were performed. There was no change in serum creatinine, leukocyte count, serum albumin, or transaminase levels, but we found a statistically significant reduction of hemoglobin after conversion (13.2 ± 1.6 g/dL with MMF vs. 12.5 ± 1.3 g/dL when receiving EC‐MPS). The GSRS total mean score was 16 ± 12 with MMF vs. 8 ± 5 with EC‐MPA (p